|
1. BIOLOGIE
|
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
Statement from Health Canada on Glyphosate [Health Canada]
|
|
|
|
|
|
After a thorough scientific review, we have concluded that the concerns raised by the objectors could not be scientifically supported when considering the entire body of relevant data. The objections raised did not create doubt or concern regarding the scientific basis for the 2017 re-evaluation decision for glyphosate. Therefore, the Department’s final decision will stand.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
3.8 PRÉVENTION - ALIMENTATION
|
|
|
Our milestones: Europe’s search for an anti-cancer diet [Cancer Research UK]
|
|
|
|
|
|
Using money from Cancer Research UK and other funders such as the European Union, researchers in Oxford and Norfolk began adding to the EPIC database, linking their results with those collected at other research centres across Europe. Almost 30 years later, the results from EPIC have shaped our understanding of diet and cancer. And surprisingly, they’ve taught us more about what not to eat to help reduce our risk of cancer.
|
|
|
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
Come One, Come All to These Kinases [In the Pipeline]
|
|
|
|
|
|
Why do some proteins in a family prove very hard to target, while others bind a whole list of inhibitors? This paper takes a look at a particularly dramatic example in the kinase field. That’s a good place for studying such things, since there are a lot of kinases out there, and a lot of kinase inhibitors.
|
|
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
Uncovering more options in cancer immunotherapy [Emory University]
|
|
|
|
|
|
Xiulei Mo, PhD and colleagues created a system that can test whether compounds enhance the ability of human immune cells to suppress cancer cell growth. They call it HTiP, for "High-Throughput Immunomodulator Phenotypic Screening Platform." The HTiP system uses a mixture of human immune cells, combined with cancer cells carrying a known growth-driving mutation.
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
Here’s what happened when I tried to develop a new drug for a deadly cancer. [Washington Post]
|
|
|
|
|
|
Still, I’m proud of our work; that we took the shot. We developed the first molecules against a novel therapeutic target, broke new ground in the chemistry and biology of a key biochemical system and did it faster than industry standards despite our initial inexperience. We ran the go/no-go experiment and the results were negative. No go. In this field unfortunately, that’s how it goes.
|
|
|
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
Big Pharma Faces the Curse of the Billion-Dollar Blockbuster [Bloomberg]
|
|
|
|
|
|
The biggest pharmaceutical companies count on multibillion-dollar drugs to fund their expensive research units and justify high share prices. But now investors want more, demanding that companies queue up the next crop of top products before the current generation even hits peak profitability.
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Drug pricing conversations must take the cost of innovation into consideration [STAT]
|
|
|
|
|
|
We must ultimately tackle the fundamental question of how much innovation we are willing to pay for. This conversation must be informed by the economic realities underpinning the business model of how new drugs are developed, not with invectives about the greed of drug companies or hopes that breakthrough drugs will materialize out of thin air.
|
|
|
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
|
6.12 ETHIQUE
|
|
|
|
|